Followers
0
Following
0
Blog Posts
0
Threads
10
Blogs
Threads
Portfolio
Follower
Following
2021-02-25 16:38 | Report Abuse
bamboo business is down to the drain already. Kanger is looking into other business...
2020-12-11 15:23 | Report Abuse
@NPRA1985 The English name of the company is available on the website that you provided. No translation is needed.
2020-12-11 15:18 | Report Abuse
@NPRA1985 MOU is such an important agreement. How comes Kanger made such a big mistake? or the company is fake?
2020-12-11 15:02 | Report Abuse
@NPRA1985 According to the link, the subsidiary/JV of Sinopharm Group is SINOPHARM GROUP HUNAN CHANGDE MEDICAL EQUIPMENT CO. LTD. But the one works with Kanger is SINOPHARM GROUP HUNAN CHANGDE MEDICAL CO. LTD. Two companies are different with the word "Equipment".
2020-12-11 14:55 | Report Abuse
@Jusloh Kanger collaborates with SINOPHARM GROUP HUNAN CHANGDE MEDICAL CO. LTD. It is nothing to do with SINOPHARM GROUP HUNAN CHANGDE MEDICAL EQUIPMENT CO. LTD. Two different companies I think.
2020-12-11 14:00 | Report Abuse
So far cannot find any evidence..
2020-12-11 14:00 | Report Abuse
Can you prove that it is subsidiary of Sinopharm?
2020-12-11 13:55 | Report Abuse
Sinopharm Group Hunan Changde Medical Co Ltd is not subsidiary of Sinopharm.
2020-12-11 13:24 | Report Abuse
Kanger is indeed a fake vaccine counter.
GeorgeChiros Sinopharm has nothing to do with Kanger!!!!
Sinopharm's vaccine approval would not have any legitimate impact on Kanger as Kanger's Proxy Agreement with middleman Shenzen Public Health Technology Co. Ltd. - SZPHT (per announcement 22nd Sep. 2020). As at to date, SZPHT has not obtained any dealership/ distribution rights from Sinopharm for Kanger after almost 3 months long announcement. Moreover, Hunan Chande Medical Co. Ltd. (per Proxy Agreement) does not exist! Hunan Chande Medical Equipment Co. Ltd. does exist! But sells medical devices n equipment!
11/12/2020 12:20 PM
Stock: [KANGER]: KANGER INTERNATIONAL BERHAD
2021-03-02 15:10 | Report Abuse
The market gives a very strong signal to the company directors that private placement is not preferred.